Skip to content

US · 21 CFR

21 CFR Part 601

Licensing

eCFR, up to date as of 2026-11-12

Table of contents

  1. 601.2Applications for biologics licenses; procedures for filing.
  2. 601.3Complete response letter to the applicant.
  3. 601.4Issuance and denial of license.
  4. 601.5Revocation of license.
  5. 601.6Suspension of license.
  6. 601.7Procedure for hearings.
  7. 601.8Publication of revocation.
  8. 601.9Licenses; reissuance.
  9. 601.12Changes to an approved application.
  10. 601.14Regulatory submissions in electronic format.
  11. 601.15Foreign establishments and products: samples for each importation.
  12. 601.20Biologics licenses; issuance and conditions.
  13. 601.21Products under development.
  14. 601.22Products in short supply; initial manufacturing at other than licensed location.
  15. 601.27Pediatric studies.
  16. 601.28Annual reports of postmarketing pediatric studies.
  17. 601.29Guidance documents.
  18. 601.30Scope.
  19. 601.31Definition.
  20. 601.32General factors relevant to safety and effectiveness.
  21. 601.33Indications.
  22. 601.34Evaluation of effectiveness.
  23. 601.35Evaluation of safety.
  24. 601.40Scope.
  25. 601.41Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.
  26. 601.42Approval with restrictions to assure safe use.
  27. 601.43Withdrawal procedures.
  28. 601.44Postmarketing safety reporting.
  29. 601.45Promotional materials.
  30. 601.46Termination of requirements.
  31. 601.50Confidentiality of data and information in an investigational new drug notice for a biological product.
  32. 601.51Confidentiality of data and information in applications for biologics licenses.
  33. 601.70Annual progress reports of postmarketing studies.
  34. 601.90Scope.
  35. 601.91Approval based on evidence of effectiveness from studies in animals.
  36. 601.92Withdrawal procedures.
  37. 601.93Postmarketing safety reporting.
  38. 601.94Promotional materials.
  39. 601.95Termination of requirements.
Cover page and contents (original)

Authority:15 U.S.C. 1451-1561; 21 U.S.C. 321, 351, 352, 353, 355, 356b, 360, 360c-360f, 360h-360j, 371, 374, 379e, 381; 42 U.S.C. 216, 241, 262, 263, 264; sec 122, Pub. L. 105-115, 111 Stat. 2322 (21 U.S.C. 355 note), sec 7002(e), Pub. L. 111-148, 124 Stat. 817, as amended by sec. 607, Division N, Pub. L. 116-94, 133 Stat. 3127.

Source:38 FR 32052, Nov. 20, 1973, unless otherwise noted.

Source: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · retrieved 2026-11-16

Weekly Newsletter

Get the week's FDA, EU and MFDS inspection findings

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Confirm by email to start · Unsubscribe any time